Autism Disorder and Treatment Market Size, Share, Top Vendors, Industry Trends, Growth, Recent Developments, Technology Forecast to 2030
CAGR Of 4.37% to Develop Autism Disorder and Treatment
Market Growth
Autism Disorder and Treatment Market – Overview
Autism cases have been on the rise in the recent years, but
the treatment options for the ailment are few and not effective enough to
combat the disease. Market reports linked to the healthcare sector made
available by Market Research Future along with published reports on other
sectors have been recently published along with a report on this market. The Autism
Disorder and Treatment Market is anticipated to grow at a CAGR of 4.37
percent in the forecast period.
Availability of better detection and diagnostic facilities
have increased the industry scope for autism
treatment. Increased funding for medical research and development
purposes have raised the opportunities for development of drugs and treatment
options of autism. Heightened levels of awareness of autism have increased the
investment level for the expansion of the industry which will continue through
the review period till 2023.
Industry Segments
The Autism Disorder and Treatment Market has been
segmented on the basis of treatment type, type and drugs.
·
By type the market is segmented into the
segments of Pervasive Developmental Disorder, Asperger Syndrome, and others.
·
The treatment type segment of the autism
disorder and treatment industry is segmented into hyperbaric oxygen therapy
ABA (applied behavioral analysis), chelation therapy and oxytocin therapy among
others.
·
Lastly on the basis of drugs, the
industry segmented into anti-psychotic, anti-convulsant, SSRIs, stimulants. The
Anti-psychotics segment is additionally segmented Risperidone and into Abilify
(aripiprazole).
Key Companies:
·
Eli Lilly and Company,
·
Allergan,
·
Consern Pharma Private Limited,
·
Merck & CO Inc.,
·
Pfizer Inc.,
·
Teva Pharmaceutical Industries Ltd.,
·
Novartis AG,
·
Bristol-Myers Squibb,
·
Johnson & Johnson Services, Inc.,
·
Otsuka Holdings Co., Ltd and
·
Coronis Partners Ltd
are a few of the important players in the market.
Detailed Regional Analysis
The autism disorder & treatment industry globally is
segmented into the following regions such as Europe, Americas, Asia Pacific,
the Middle East and Africa. The Americas hold the major market portion followed
by the European region. In the Americas region, the North American region is
the largest regional market owing to the growing screening of autism cases in
this particular region. Moreover, the expected launch and approval of the
atypical anti-psychotics such as Namenda and Latuda is estimated to lead to
better sales in the U.S. after approval. The Asia Pacific region is estimated
to be the most rapidly developing regional market while the Middle East &
African region has demonstrated stable growth during the forecast period. With
increased detection of autism disorder cases around the world, the industry
will be prompted to grow in response so as to treat and control this particular
ailment.
Global Competitive Analysis
Contenders who are a part of the industry have devised their
corporate strategy blueprint in a way that that can bring the best outcomes for
development in the current scenario. With the ability to sustain their
competitive edge being one of the primary factors driving their efforts, the
scope for growth in the industry appears to be promising through the forecast
period. The rising affinity for diversification in the market, has indirectly
enabled the players to utilize the many prospects available. This specific
trend has enabled portfolio improvements along with the affinity for diversification
in the sector, which has helped the market competitors tremendously in this
industry. The companies in this particular industry are also trying to maintain
and enhance financial liquidity that can be instrumental to invest in growth
strategies as and when they become available.
Industry Updates:
·
Mar 2018 A path breaking drug that addresses the
root causes of autism could be accessible in the UK within five years because
initial trial results for Balovaptan have fascinated US regulators, that the
drug has been given an “accelerated status”, making way for faster approval.
The cure which has been developed by the drug giant Roche acts as a brain
receptor for the hormone vasopressin, which is understood to have influence on
social bonding. The trial spanned over a time period of 12-weeks which comprised
of 223 men in which one group had the placebo and the other group had the
treatment. Individuals who took the drug scored significantly higher on social behavioural
scales.
Related Report-
·
Dental
Consumables Market Research Report- North America Forecast till 2027
·
Smart
Contact Lenses Market Research Report- Global Forecast Till 2027
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment